The CCK8 assay results showed that PCSK9 knockdown rendered HCC cells insensitive to flubendazole treatment, whereas PCSK9 overexpression augmented the sensitivity of HCC cells to flubendazole treatment (Figure 4A and 4B). Here, PCSK9 is linked to hepatocellular carcinoma.